Osilodrostat
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB11837 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 90 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | familial generalized lentiginosis | KG + DL |
| 2 | congenital multiple café-au-lait macules-increased sister chromatid exchange syndrome | KG + DL |
| 3 | acromelanosis | KG + DL |
| 4 | gastrocutaneous syndrome | KG + DL |
| 5 | leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome | KG + DL |
| 6 | Moynahan syndrome | KG + DL |
| 7 | rhabdoid tumor | KG + DL |
| 8 | X-linked lymphoproliferative disease due to SH2D1A deficiency | KG + DL |
| 9 | osteopathia striata-pigmentary dermopathy-white forelock syndrome | KG + DL |
| 10 | peripheral nerve schwannoma | KG + DL |
| 11 | schwannoma of twelfth cranial nerve | KG + DL |
| 12 | sympathetic neurilemmoma | KG + DL |
| 13 | microcystic/reticular schwannoma | KG + DL |
| 14 | trigeminal schwannoma | KG + DL |
| 15 | A20 haploinsufficiency | KG + DL |
| 16 | benign neoplasm of adrenal gland | KG + DL |
| 17 | immune dysregulation with inflammatory bowel disease | KG + DL |
| 18 | Steel syndrome | KG + DL |
| 19 | hemophagocytic syndrome associated with an infection | KG + DL |
| 20 | acquired hemophagocytic lymphohistiocytosis associated with malignant disease | KG + DL |
| 21 | autosomal recessive familial Mediterranean fever | KG + DL |
| 22 | autosomal ichthyosis syndrome with fatal disease course | KG + DL |
| 23 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | KG + DL |
| 24 | proximal myopathy with extrapyramidal signs | KG + DL |
| 25 | hypophosphatasia | KG + DL |
| 26 | Gaucher disease | KG + DL |
| 27 | skeletal muscle disease | KG + DL |
| 28 | familial apolipoprotein C-II deficiency | KG + DL |
| 29 | polycystic kidney disease 3 with or without polycystic liver disease | KG + DL |
| 30 | familial Mediterranean fever, autosomal dominant | KG + DL |
| 31 | autosomal dominant keratitis | KG + DL |
| 32 | primary immunodeficiency due to a genetic defect in innate immunity | KG + DL |
| 33 | familial Mediterranean fever | KG + DL |
| 34 | inclusion myopathy | KG + DL |
| 35 | autosomal dominant Alport syndrome | KG + DL |
| 36 | lipoatrophic diabetes | KG + DL |
| 37 | neurofibromatosis | KG + DL |
| 38 | renal-hepatic-pancreatic dysplasia | KG + DL |
| 39 | hemophagocytic lymphohistiocytosis | KG + DL |
| 40 | autosomal dominant brachyolmia | KG + DL |
| 41 | extracutaneous mastocytoma | KG + DL |
| 42 | lipodystrophy-intellectual disability-deafness syndrome | KG + DL |
| 43 | citrullinemia, type II, adult-onset | KG + DL |
| 44 | arthrogryposis, distal, | KG + DL |
| 45 | X-linked lymphoproliferative syndrome | KG + DL |
| 46 | TSH producing pituitary tumor | KG + DL |
| 47 | thoracic malformation | KG + DL |
| 48 | lipodystrophy due to peptidic growth factors deficiency | KG + DL |
| 49 | autosomal dominant complex spastic paraplegia | KG + DL |
| 50 | autosomal dominant pure spastic paraplegia | KG + DL |
(Showing top 50 of 90 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.